Skip to main content

Table 2 Patient and donor characteristics in the prospective study

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Characteristics All patients MSDT   HBMT  
MRDneg MRDpos MRDneg MRDpos
Number of patients 340 62 20   202 56  
Median age (range), years 32 (3–65) 39 (4–55) 41.5 (7–62) 0.612 30 (3–65) 26 (4–61) 0.151
Weight (range), kg 62 (15.5–140) 63 (15.5–91) 65.25 (28–95) 0.631 62 (17–140) 58 (19–92) 0.090
Male, n (%) 208 (61.2%) 32 (51.6%) 15 (75.0%) 0.066 127 (62.9%) 34 (60.7%) 0.768
Diagnosis, n (%)     0.146    0.603
 De novo AML 318 (93.5%) 61 (98.4%) 18 (90.0%)   187 (92.6%) 52 (92.9%)  
 Secondary AML 22 (6.5%) 1 (1.6%) 2 (10.0%)   15 (7.4%) 4 (7.1%)  
Disease status, n (%)        0.165
 CR1 293 (86.2%) 56 (90.3%) 15 (75.0%) 0.080 177 (87.6%) 45 (80.4%)  
 CR > 1 47 (13.8%) 6 (9.7%) 5 (25.0%)   25 (12.4%) 11 (19.6%)  
FLT3-ITD mutation     0.390    0.610
 Yes 49 (14.4%) 11 (17.7%) 2 (10.0%)   27 (13.4%) 9 (16.1%)  
 No 291 (85.6%) 51 (82.3%) 18 (90.0%)   175 (86.6%) 47 (83.9%)  
Cytogenetics     0.500    0.277
 Favorable 43 (12.6%) 7 (11.3%) 1 (5.0%)   28 (13.9%) 7 (12.5%)  
 Intermediate 263 (77.4%) 50 (80.6%) 16 (80.0%)   157 (77.7%) 40 (71.4%)  
 Adverse 34 (10.0%) 5 (8.1%) 3 (15.0%)   17 (8.4%) 9 (16.1%)  
Conditioning regimen, n (%)
 MA 340 (100%) 62 (100%) 20 (100%)   202 (100%) 56 (100%)  
HLA-A-, B-, and DR-mismatched grafts, n (%)        0.599
 0 84 (24.7%) 62 (100%) 20 (100%)   2 (1.0%) 0  
 1 7 (2.1%) 0 0   5 (2.5%) 2 (3.6%)  
 2 31 (9.1%) 0 0   22 (10.9%) 9 (16.1%)  
 3 218 (64.1%) 0 0   173 (85.6%) 45 (80.4%)  
Donor-recipient sex-matched grafts, n (%)
 Male–male 136 (40.0%) 15 (24.2%) 6 (30.0%)   94 (46.5%) 21 (37.5%)  
 Male–female 86 (25.3%) 14 (22.6%) 3 (15.0%)   55 (27.2%) 14 (25.0%)  
 Female–male 75 (22.1%) 18 (29.0%) 2 (10.0%)   33 (16.3%) 15 (26.8%)  
 Female–female 43 (12.6%) 15 (24.2%) 9 (45.0%)   20 (9.9%) 6 (10.7%)  
Donor-recipient relationship, n (%)        0.283
 Parent–child 132 (38.8%) 0 0   99 (49.0%) 33 (58.9%)  
 Sibling–sibling 153 (45.0%) 62 (100%) 20 (100%)   61 (30.2%) 10 (17.9%)  
 Child–parent 49 (14.4%) 0 0   37 (18.3%) 12 (21.4%)  
 Other 6 (1.8%) 0 0   5 (2.5%) 1 (1.8%)  
ABO matched grafts, n (%)        0.344
 Matched 179 (52.6%) 40 (64.5%) 14 (70.0%) 0.660 97 (48.0%) 28 (50.0%)  
 Major mismatch 70 (20.6%) 10 (16.1%) 4 (20.0%)   45 (22.3%) 11 (19.6%)  
 Minor mismatch 72 (21.2%) 8 (12.9%) 2 (10.0%)   46 (22.8%) 16 (28.6%)  
 Bi-directional mismatch 19 (5.6%) 4 (6.5%) 0   14 (6.9%) 1 (1.8%)  
EBMT score, n (%)     0.125    0.546
 0 2 (0.6%) 1 (1.6%) 1 (5.0%)   0 0  
 1 66 (19.4%) 21 (33.9%) 6 (30.0%)   31 (15.3%) 8 (14.3%)  
 2 145 (42.6%) 28 (45.2%) 6 (30.0%)   90 (44.6%) 21 (37.5%)  
 3 91 (26.8%) 11 (17.7%) 4 (20.0%)   58 (28.7%) 18 (32.1%)  
 4 30 (8.8%) 1 (1.6%) 3 (15.0%)   20 (9.9%) 6 (10.7%)  
 5 6 (1.8%) 0 0   3 (1.5%) 3 (5.4%)  
Cell compositions in allografts
 Infused nuclear cells, (range) 108/kg 7.83 (2.27–16.66) 7.59 (5.18–14.93) (5.18–14.93) 7.22 (2.27–9.29) 0.201 7.88 (3.93–15.97) 8.17 (3.44–16.66) 0.517
 Infused CD34+ cells, (range) 106/kg 2.55 (0.22–10.95) 2.53 (0.41–6.43) 2.65 (0.90–5.47) 0.829 2.49 (0.22–10.95) 2.78 (0.38–7.20) 0.340
DLI after transplant, n (%)
 For relapse prophylaxis and intervention 32 (9.4%) 5 (8.1%) 4 (20.0%) 0.211 8 (4.0%) 14 (25.0%) <0.001
 For relapse treatment 8 (2.4%) 2 (3.2%) 2 (10.0%) 0.249 3 (1.5%) 2 (3.6%) 0.297
  1. Abbreviations: HLA human leukocyte antigen, MSDT HLA-matched sibling donor transplantation, HBMT unmanipulated haploidentical blood and marrow transplantation, MRD minimal residual disease, neg negative, pos positive, AML acute myeloid leukemia, CR complete remission, MA myeloablative regimen, EBMT European Group for Blood and Marrow Transplantation, DLI donor lymphocyte infusions